Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Denali Therapeutics (DNLI) EBIT (2017 - 2025)

Denali Therapeutics (DNLI) has disclosed EBIT for 9 consecutive years, with -$137.4 million as the latest value for Q4 2025.

  • Quarterly EBIT fell 5.79% to -$137.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$555.3 million through Dec 2025, down 13.95% year-over-year, with the annual reading at -$555.3 million for FY2025, 13.95% down from the prior year.
  • EBIT for Q4 2025 was -$137.4 million at Denali Therapeutics, roughly flat from -$137.4 million in the prior quarter.
  • The five-year high for EBIT was $170.5 million in Q2 2023, with the low at -$145.6 million in Q1 2025.
  • Average EBIT over 5 years is -$93.8 million, with a median of -$115.2 million recorded in 2023.
  • The sharpest move saw EBIT surged 377.59% in 2023, then crashed 168.39% in 2024.
  • Over 5 years, EBIT stood at -$77.1 million in 2021, then tumbled by 36.6% to -$105.3 million in 2022, then fell by 25.85% to -$132.6 million in 2023, then increased by 2.06% to -$129.8 million in 2024, then dropped by 5.79% to -$137.4 million in 2025.
  • According to Business Quant data, EBIT over the past three periods came in at -$137.4 million, -$137.4 million, and -$135.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.